Overview
Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis
Status:
Completed
Completed
Trial end date:
2010-06-01
2010-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to placebo in patients with acute adenoviral keratoconjuncivitis.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Laboratoires Thea
Criteria
Inclusion Criteria:- Written informed consent
- Male or female aged from 18 to 80 years old
- Acute adenoviral keratoconjunctivitis
Exclusion Criteria:
- Active ocular allergy
- Ocular herpès disease
- History of bacterial conjunctivitis / blepharoconjunctivitis within the last month
before the inclusion visit